Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Crinetics Pharmaceuticals — Operating loss by Quarter
Crinetics Pharmaceuticals — Operating loss ($M) ($M)
Vertex Pharmaceuticals Crinetics Pharmaceuticals — Operating loss: -$132M in Q2 2026, up 2.6% from a year earlier.
Where the Q2 2026 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001699813 Crinetics Pharmaceuticals).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Crinetics Pharmaceuticals — Operating loss ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | -132 | +2.6% | SEC Filing ↗ |
| Q1 2026 | Mar 31, 2026 | -140 | +26.0% | SEC Filing ↗ |
| Q4 2025 | Dec 31, 2025 | -134 | +41.1% | SEC Filing ↗ |
| Q3 2025 | Sep 30, 2025 | -143 | +62.4% | SEC Filing ↗ |
| Q2 2025 | Jun 30, 2025 | -129 | +56.0% | SEC Filing ↗ |
| Q1 2025 | Mar 31, 2025 | -111 | +51.5% | SEC Filing ↗ |
| Q4 2024 | Dec 31, 2024 | -94.7 | +51.2% | SEC Filing ↗ |
| Q3 2024 | Sep 30, 2024 | -87.8 | +48.9% | SEC Filing ↗ |
| Q2 2024 | Jun 30, 2024 | -82.8 | +56.2% | SEC Filing ↗ |
| Q1 2024 | Mar 31, 2024 | -73.5 | +53.3% | SEC Filing ↗ |
| Q4 2023 | Dec 31, 2023 | -62.7 | +31.7% | SEC Filing ↗ |
| Q3 2023 | Sep 30, 2023 | -59.0 | +35.7% | SEC Filing ↗ |
| Q2 2023 | Jun 30, 2023 | -53.0 | +23.1% | SEC Filing ↗ |
| Q1 2023 | Mar 31, 2023 | -48.0 | +41.8% | SEC Filing ↗ |
| Q4 2022 | Dec 31, 2022 | -47.6 | +54.0% | SEC Filing ↗ |
| Q3 2022 | Sep 30, 2022 | -43.5 | +56.2% | SEC Filing ↗ |
| Q2 2022 | Jun 30, 2022 | -43.0 | +65.0% | SEC Filing ↗ |
| Q1 2022 | Mar 31, 2022 | -33.8 | +47.6% | SEC Filing ↗ |
| Q4 2021 | Dec 31, 2021 | -30.9 | +41.7% | SEC Filing ↗ |
| Q3 2021 | Sep 30, 2021 | -27.8 | +50.7% | SEC Filing ↗ |
| Q2 2021 | Jun 30, 2021 | -26.1 | +54.1% | SEC Filing ↗ |
| Q1 2021 | Mar 31, 2021 | -22.9 | +28.9% | SEC Filing ↗ |
| Q4 2020 | Dec 31, 2020 | -21.8 | +43.2% | SEC Filing ↗ |
| Q3 2020 | Sep 30, 2020 | -18.5 | +21.1% | SEC Filing ↗ |
| Q2 2020 | Jun 30, 2020 | -16.9 | +26.9% | SEC Filing ↗ |
| Q1 2020 | Mar 31, 2020 | -17.8 | +77.1% | SEC Filing ↗ |
| Q4 2019 | Dec 31, 2019 | -15.2 | +61.4% | SEC Filing ↗ |
| Q3 2019 | Sep 30, 2019 | -15.2 | +88.7% | SEC Filing ↗ |
| Q2 2019 | Jun 30, 2019 | -13.3 | +134.9% | SEC Filing ↗ |
| Q1 2019 | Mar 31, 2019 | -10.0 | +81.6% | SEC Filing ↗ |
| Q4 2018 | Dec 31, 2018 | -9.43 | – | SEC Filing ↗ |
| Q3 2018 | Sep 30, 2018 | -8.07 | – | SEC Filing ↗ |
| Q2 2018 | Jun 30, 2018 | -5.68 | – | SEC Filing ↗ |
| Q1 2018 | Mar 31, 2018 | -5.53 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Crinetics Pharmaceuticals — Operating loss ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crinetics-op-inc
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.